

Bizapedia.com - Human Validation
















COMPANIESPEOPLEPRODUCTS/SERVICESTRADEMARKSADDRESSESPHONE BOOK




            Our system has detected a high number of page requests from your IP Address, please prove to us that you are a human to continue using our website.
        
























                            Please send me to the search subscription offer page after I successfully answer the word challenge.
                        









BIZAPEDIAPRO SEARCHPerform unlimited searches via ouradvanced search form withBizapedia Pro Search.FIND OUT MORE >BIZAPEDIAPRO DATABuild custom data listsfor one or many stateswith Bizapedia Pro Data.FIND OUT MORE >


Copyright © 2012-2017 · Bizapedia.com · All rights reserved.BlogPro SearchPro APIContact UsTerms of UsePrivacy PolicySitemapDesktop Version























 







Trieza Therapeutics, Inc. - Pharmaceuticals- Cordo  FormDs.com - SEC filings of fundraisings and investments in hedge funds, private equity firms, startups, and growing companies 











 FormDs.com 





 Newest
 Filter
 Local




 









Trieza Therapeutics, Inc.

      Industry: Pharmaceuticals
      (See others in industry)

Address:



    1030 Massachusetts Avenue Suite 210 
    Cambridge, MA, 02138Phone: 617-588-4150 




Filings



Date
FilingType
Reported Sold
Incremental Cash 
Type
Exemptions
Link to Raw Filing




	2016-12-05


New


$1


$1


Equity Only


06b


SEC link




	2016-12-05


New


$5,999,000


$5,999,000


Debt Only


06b


SEC link






Directors and Executives (Current and Past)



Name
Role



 David Cordo 
 Executive 


 Luke Evnin 
 Director 


 Daniel Hicklin 
 Director, Executive 












Bizapedia.com - Human Validation
















COMPANIESPEOPLEPRODUCTS/SERVICESTRADEMARKSADDRESSESPHONE BOOK




            Our system has detected a high number of page requests from your IP Address, please prove to us that you are a human to continue using our website.
        
























                            Please send me to the search subscription offer page after I successfully answer the word challenge.
                        









BIZAPEDIAPRO SEARCHPerform unlimited searches via ouradvanced search form withBizapedia Pro Search.FIND OUT MORE >BIZAPEDIAPRO DATABuild custom data listsfor one or many stateswith Bizapedia Pro Data.FIND OUT MORE >


Copyright © 2012-2017 · Bizapedia.com · All rights reserved.BlogPro SearchPro APIContact UsTerms of UsePrivacy PolicySitemapDesktop Version














	Abzena grants Trieza Therapeutics exclusive, worldwide rights to an undisclosed antibody sequence for use with Trieza's viral vector technology to develop cancer treatments  - Deal Profile - BioCentury



































Publications
archives
BCIQ
Conferences
version 4.3.15.600





Free Trial / Subscribe


SIGN IN



English
简体中文
日本語
한국어







Biocentury





Menu





                                        Home
                                        
+




                                        Publications
                                        
+



Publications Home >


BioCentury>


BC Innovations>


BC Extra>


BC Week In Review>


Current Issues>




Archives 
                                        
+



Archives Home >


Basic Search>


Advanced Search>


Back Issues>




BCIQ
                                        
+



BCIQ Home >


Overview>


Pipeline Analyst>


Financial Analyst>


Company Analyst>


Deal Analyst>




Conferences 
                                        
+




Conferences Home >


Newsmakers


Bio€quity Europe


Future Leaders


China Healthcare Summit


Other Industry Events





eLearning 
                                        
+



eLearning Home >


Videos>


White Papers>


                                            Follow Us
                                            


























BCIQ / Deal Profile


BCIQ Overview   |    
                        Settings   |   
                        Support
















Abzena grants Trieza Therapeutics exclusive, worldwide rights to an undisclosed antibody sequence for use with Trieza's viral vector technology to develop cancer treatments 






Abzena plc
U.K. / Small-Cap Biopharma (
                            
                            $40.8m on 12/16/2016 [market cap]

Licensor



This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!







Trieza Therapeutics Inc.
U.S. / Private Biopharma

Licensee



This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!










Active 
Sample


01/01/2009
announced























© 2017 BioCentury Inc. All Rights Reserved.     
            Terms & Conditions  |  Privacy Policy























Home - Therapeutics Inc.
























































About
Partnering / Investors
Careers
Contact
 








Meet your milestonesThe only full-service dermatology CRO that takes products from concept to approvalDoes your product have a reason to be?Our philosophy extends to both our clients and ourselves: be the best we can beMeet with us




You may wonder what makes us different from other CROs...
OVER 90% OF WHAT WE DO IS DERMATOLOGY.
At Therapeutics we nurture your ideas with thoughtfully integrated solutions. We aim to be your preferred partner.



Let us lead your dermatology product development program through the complex maze of non-clinical, clinical and regulatory hurdles to an FDA approval.Get started 
 

Strategy
CRO Services
Technology Assessment
Our Top 10
Press Room
 









© 2016 Therapeutics, Inc.   Legal  |  PRIVACY
858-571-1800
9025 Balboa Ave., Suite 100, San Diego, CA 92123



© 2016 Therapeutics, Inc.
9025 Balboa Ave., Suite 100, San Diego, CA 92123
858-571-1800

Legal  |  PRIVACY


















	Trieza Therapeutics Inc. - Company Profile - BioCentury




























































Publications
archives
BCIQ
Conferences
version 4.3.15.600





Free Trial / Subscribe


SIGN IN



English
简体中文
日本語
한국어







Biocentury





Menu





                                        Home
                                        
+




                                        Publications
                                        
+



Publications Home >


BioCentury>


BC Innovations>


BC Extra>


BC Week In Review>


Current Issues>




Archives 
                                        
+



Archives Home >


Basic Search>


Advanced Search>


Back Issues>




BCIQ
                                        
+



BCIQ Home >


Overview>


Pipeline Analyst>


Financial Analyst>


Company Analyst>


Deal Analyst>




Conferences 
                                        
+




Conferences Home >


Newsmakers


Bio€quity Europe


Future Leaders


China Healthcare Summit


Other Industry Events





eLearning 
                                        
+



eLearning Home >


Videos>


White Papers>


                                            Follow Us
                                            


























BCIQ / Company Profile


BCIQ Overview   |    
                        Settings   |   
                        Support















Biocentury



Print this                                                    
                        
















                         
                            

    

    

    
                         
                        



                            Trieza Therapeutics Inc.
                        









print preview


export


bookmark


share with colleague





















General Information
                    






 Location

Cambridge, Mass.


 Region

New England


 Country

U.S.


 Business Category

Cancer


 Year Founded

2016


 Website





 Lead Product Status

Preclinical






















 Archive Items are loading
                            













 Financial Information
                        






 Financing
                                                Summary







 Financing Details







 Earnings
                                    Summary
                                






 Stocks Annual Chart
                                





















 Pipeline Information
                        






 Pipeline
                                                Summary







 Pipeline Details




















 Deals Information
                        






 Deals
                                                Summary







 Deals Details






















About Biocentury


Company Overview


Management


Editorial & Research




Contact


Contact Us


Advertising & Sponsorship


Career Opportunities




Support


Forgot Password


Customer Service


Reprints


FAQs




Products & Solutions


Products Overview


Publications


Archives


BCIQ


Conferences


eLearning


RSS Feeds




Legal


User Agreement


Terms of Use


Privacy Policy


Your California Privacy Rights


Use of Images

Follow Us
                            











What is BioCentury?
BioCentury employs a fully integrated multimedia platform — including publications, video, online data solutions and conferences — to provide its audience with authoritative and up-to-date intelligence about corporate strategy, partnering, emerging technology, clinical data, public policy and the financial markets.

Sign in
Free Trial












© 2017 BioCentury Inc. All Rights Reserved.
     
                        Terms & Conditions
                          |  
                        Privacy Policy











Set Email Alert






dummy














Telangana news updates | Hyderabad live news updates |  Business News live | Telangana news updates | latest breaking news HyderabadNational News live | Latest news on telangana | Telangana news updates Andhra Pradesh News live | Andhra Pradesh Latest news | Latest news on telangana | Telangana news updates | International News Live |latest international news Updates | Legal News Live |latest legal news Updates | Editorial News Live |latest editorial news Updates | Sports News Live Updates |latest editorial news Updates | Health News Live Updates |latest health news Updates | pharma News Live Updates |latest pharma news Updates | Woman News Live Updates |latest woman news Updates| Entertainment News Live Updates |latest entertainment news | Education-and-career News Live Updates |latest education-and-career News| indianwhitepaper Gallery| live News Gallery | breaking news Gallery indianwhitepaper vedios | live News videos | breaking news videos




































 










































Business

National

Andhra Pradesh

Telangana

International

Legal

Editorial

Sports

Health

Pharma

woman

Entertainment

Education and career







 



Home / News / pharma






Abzena grants composite human antibody technology licence to Trieza Therapeutics



												Dec 25, 2016 
											
Posted by Admin









Cambridge, UK Abzena plc, a life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed a licence agreement with Trieza Therapeutics, Inc (Trieza). Trieza is a start-up biotechnology company specialising in the discovery and development of immunomodulatory oncolytic viruses based in Cambridge, MA, USA.Abzena has granted Trieza an exclusive worldwide, royalty bearing, sub-licensable licence to an undisclosed antibody sequence, which was created using the Group’s Composite Human Antibody technology, for exploitation in conjunction with Trieza’s viral vector technology to develop novel therapies in oncology.Abzena could receive up to $35m in development and commercial milestone payments as well as royalties on the sale of licensed products containing the Abzena sequence. Dr John Burt, Abzena’s CEO, commented: “This new licence deal with Trieza provides the opportunity for Abzena to benefit from the commercialisation of one of the assets originally developed by the Group to exemplify its proprietary antibody humanization and deimmunisation technology.  Our Abzena inside portfolio already has eleven products in the clinic that have benefitted from this technology.”Dr Dan Hicklin, Trieza Therapeutics’ CEO, said: “We are pleased to enter this relationship with Abzena. Access to Abzena’s technology will accelerate the development of Trieza’s portfolio of immunotherapeutic oncolytic virus product candidates”.












 A- A A+













Latest Videos








































































All Videos





Photo Gallery





All Photos

















Popular News










Amid fear of more defections, Congress herds its Gujarat MLAs to Bengaluru ahead of Rajya Sabha polls



															Jul 29, 2017 

														










Defection, a constitutional sin



															Jul 28, 2017 

														










Stop Shadi ke Shaheed  



															Jul 28, 2017 

														










The web counselling abruptly stopped for technical problem



															Jul 28, 2017 

														










Opposition using Dalits as pawns: Jawahar



															Jul 28, 2017 

														










AP businessmen reject Odisha for Andhra Pradesh 



															Jul 28, 2017 

														









 




Scroll To Top




 



Trieza Therapeutics, Inc.: CEO and Executives - Bloomberg







































  





















































































July 28, 2017 10:04 PM ET

Company Overview of Trieza Therapeutics, Inc.



SnapshotPeople 




OverviewBoard MembersCommittees



Key Executives for Trieza Therapeutics, Inc.
NameBoard RelationshipsTitleAgeDaniel J. Hicklin Ph.D.7 RelationshipsPresident and Director--
Trieza Therapeutics, Inc. Board Members*
NameBoard RelationshipsPrimary CompanyAgeDaniel J. Hicklin Ph.D. 7 RelationshipsTrieza Therapeutics, Inc.--Luke B. Evnin Ph.D. 100 RelationshipsBlade Therapeutics, Inc.54View All Board Members
Trieza Therapeutics, Inc. Executive Committees*
Committee NameChairpersonBoard RelationshipsMembersThere is no committee data available.
*Data is at least as current as the most recent Definitive Proxy.
Request Profile Update

















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



CEO COMPENSATION IN THIS INDUSTRY  Industry Range










INDUSTRY EXECUTIVE CHANGESThere is no Executive Change data available.Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Trieza Therapeutics, Inc., please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close


























